Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Oct;39(5):1275-1283.
doi: 10.1007/s10637-020-01025-x. Epub 2021 Mar 11.

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study

María Eugenia Olmedo  1 , Martin Forster  2 , Victor Moreno  3 , María Pilar López-Criado  4 , Irene Braña  5 , Michael Flynn  2 , Bernard Doger  3 , María de Miguel  6 , José Antonio López-Vilariño  7 , Rafael Núñez  7 , Carmen Kahatt  7 , Martin Cullell-Young  7 , Ali Zeaiter  7 , Emiliano Calvo  8
Affiliations
Clinical Trial

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study

María Eugenia Olmedo et al. Invest New Drugs. 2021 Oct.

Abstract

Background A phase I study found remarkable activity and manageable toxicity for doxorubicin (bolus) plus lurbinectedin (1-h intravenous [i.v.] infusion) on Day 1 every three weeks (q3wk) as second-line therapy in relapsed small cell lung cancer (SCLC). An expansion cohort further evaluated this combination. Patients and methods Twenty-eight patients with relapsed SCLC after no more than one line of cytotoxic-containing chemotherapy were treated: 18 (64%) with sensitive disease (chemotherapy-free interval [CTFI] ≥90 days) and ten (36%) with resistant disease (CTFI <90 days; including six with refractory disease [CTFI ≤30 days]). Results Ten patients showed confirmed response (overall response rate [ORR] = 36%); median progression-free survival (PFS) = 3.3 months; median overall survival (OS) = 7.9 months. ORR was 50% in sensitive disease (median PFS = 5.7 months; median OS = 11.5 months) and 10% in resistant disease (median PFS = 1.3 months; median OS = 4.6 months). The main toxicity was transient and reversible myelosuppression. Treatment-related non-hematological events (fatigue, nausea, decreased appetite, vomiting, alopecia) were mostly mild or moderate. Conclusion Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk has shown noteworthy activity in relapsed SCLC and a manageable safety profile. The combination is being evaluated as second-line therapy for SCLC in an ongoing, randomized phase III trial. Clinical trial registration www.ClinicalTrials.gov code: NCT01970540. Date of registration: 22 October, 2013.

Keywords: Lurbinectedin; PM01183; Phase I study; Small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Martin Forster has conducted consulting and advisory services, speaking or writing engagements, or public presentations for Achilles, AstraZeneca, Bayer, BMS, Celgene, Guardant Health, Merck, MSD, Nanobiotix, Novartis, Oxford VaMedix, Pfizer, Pfizer, Roche and Takeda; his institution has received research funding from AstraZeneca, Boehringer Ingelheim, MSD and Merck; in addition, Martin Foster is supported by the UCL/UCLH NIHR Biomedical Research Centre and runs early phase studies in the NIHR UCLH Clinical Research Facility supported by the UCL ECMC. Emiliano Calvo has had a company leadership role, employment relationship or ownership interest for START Madrid, Oncoart Associated, International Cancer Consultants and HM Hospitals Group; has conducted consulting and advisory services, speaking or writing engagements, or public presentations for Astellas Pharma, Novartis, Nanobiotix, Pfizer, Janssen, GLG, Merck, Medscape, BMS, Pierre-Fabre, Gilead, Cerulean, Gehrman Consulting, Boehringen-Ingelheim, Seattle Genetics, Guidepoint, AstraZeneca, Roche/Genetech, PsiOxus, Abbvie, Celgene, Servier and Amcure; has been study international principal investigator for AstraZeneca and member of study steering committees for Novartis and BeiGene, and his institution has received financial support from Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Janssen Oncology, Hospira, Lilly, Merck, Merus, Millennium, Nanobiotix, Nektar. Novartis, OncoMed, Pfizer, PharmaMar, PsiOxus Therapeutics, Puma Biotechnology, Regeneron, Roche-Genentech, Sanofi, Spectrum Pharmaceuticals, ACEA Bio, Amcure, Cytomx, H3-Biomedicine, Incyte, Kura, LOXO, Macrogenics, Menarini, Principia, Tahio, Tesaro, BeiGene, Transgene, Takeda, Innovio, MSD, Seattle Genetics, Mersana, GSK, Daiichi, Astellas, ORCA, Boston Therapeutics, Dynavax, DebioPharma, Synthon and Rigontec. José Antonio López-Vilariño, Rafael Núñez, Carmen Kahatt and Ali Zeaiter are employees and stock owners of Pharma Mar, S.A. Martin Cullell-Young is an employee of Pharma Mar, S.A. All remaining authors have declared no conflicts of interest.

Figures

Fig. 1
Fig. 1
Waterfall plot showing maximum variation of target lesions and progression-free survival in patients with at least one radiological tumor assessment (n = 26). Ten patients had target lesion decrease >30%: one with CR and nine with PR. Red stars = treatment switch to lurbinectedin alone. CR, complete response; CTFI, chemotherapy-free interval; d, days; PR, partial response
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Leal JF, Martinez-Diez M, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillen-Navarro MJ, Aviles P, Cuevas C, Garcia-Fernandez LF, Galmarini CM. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol. 2010;161(5):1099–1110. doi: 10.1111/j.1476-5381.2010.00945.x. - DOI - PMC - PubMed
    1. Santamaria Nunez G, Robles CM, Giraudon C, Martinez-Leal JF, Compe E, Coin F, Aviles P, Galmarini CM, Egly JM. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther. 2016;15(10):1–14. doi: 10.1158/1535-7163.MCT-16-0172. - DOI - PubMed
    1. Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ. Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. Cancer Res. 2016;76(22):6657–6668. doi: 10.1158/0008-5472.CAN-16-0568. - DOI - PMC - PubMed
    1. Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D'incalci M. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017;117(5):628–638. doi: 10.1038/bjc.2017.205. - DOI - PMC - PubMed
    1. Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(8):2205–2214. doi: 10.1158/1078-0432.CCR-13-1880. - DOI - PubMed

Publication types

MeSH terms

Associated data